title: Conduct disorder in an adolescent girl treated with an insulin-sensitizing agent.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kawamura
authors.forename: Akio
authors.initials: A
authors.lastname: Sakai
authors.forename: Tomomichi
authors.initials: T
authors.lastname: Endo
authors.forename: Masaki
authors.initials: M
authors.lastname: Maruta
mesh_terms: D000293:Adolescent; D000077465:Cabergoline; D019955:Conduct Disorder / Q000209:etiology* / Q000523:psychology*; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D007333:Insulin Resistance; D008572:Menarche / Q000523:psychology; D000077205:Pioglitazone; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000523:psychology; D011569:Psychiatric Status Rating Scales; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use; D014754:Violence
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077465:Cabergoline; D000077205:Pioglitazone